Allergenic Characterization of New Mutant Forms of Pru p 3 as New Immunotherapy Vaccines
Figure 2
(a) Specific IgE to Pru p 3 forms (wild type, Pru p 3.01, Pru p 3.02, and Pru p 3.03), using sera from peach-allergic patients (single or pool; 1 : 2 dilution). Blocking solution without solid phase was used as a negative control, and optical density (OD) values > 0.189 units (; mean + 3x SD = 0.108 + 3 × 0.026 OD units) were considered positive. All tests were performed in triplicate. (b) Reduction of IgE binding capacity (%) of the mutants in comparison with wild type was calculated, taking as 100% the value obtained for Pru p 3 (5 μg/mL). *The number of the patients corresponds to that in Table 1. (c) The inhibition percentage of the IgE binding capacity of wild type form is represented. Plates were covered with Pru p 3 (3 μg/mL), and Pru p 3.01, Pru p 3.0, and Pru p 3.03 were used as inhibitors. All tests were performed in triplicate.
